Connect Sign In
Aquaporin-4 Receptor Antibody
Ordering Recommendation
Aids in evaluation of neuromyelitis optica (NMO) and NMO spectrum disorders.
Methodology
Semi-Quantitative Enzyme-Linked Immunosorbent Assay
Performed
Tue, Thu
Reported
1-6 days
New York DOH Approval Status
Specimen Required
Serum Separator Tube.
Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.3 mL)
Refrigerated.
Amniotic fluid, ocular fluid peritoneal fluid, synovial fluid, or plasma. Contaminated, hemolyzed, icteric, or lipemic specimens.
After separation from cells: Ambient: 72 hours; Refrigerated: 2 weeks; Frozen: 1 month (avoid repeated freeze/thaw cycles)
Reference Interval
Effective October 3, 2016
| Negative | 2.9 U/mL or less |
| Positive | 3.0 U/mL or greater |
Interpretive Data
Approximately 75 percent of patients with neuromyelitis optica (NMO) express antibodies to the aquaporin-4 (AQP4) receptor. Diagnosis of NMO requires the presence of longitudinally extensive acute myelitis (lesions extending over 3 or more vertebral segments) and optic neuritis. While absence of antibodies to the AQP4 receptor does not rule out the diagnosis of NMO, presence of this antibody is diagnostic for NMO.
FDA
Note
Hotline History
CPT Codes
86051
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 2003121 | Aquaporin-4 Receptor Antibody | 68548-7 |
Aliases
- AQP
- AQP4
- AQP4 antibody
- AQP4 ELISA
- Aquaporin
- Devic's Ab
- Devic's Antibody
- Neuromyelitis Optica (NMO) Antibody
- Neuromyelitis Optica IgG
- NMO-IgG
- Optic Neuritix Ab
- Optic Neuritix Antibody
- Optic-Spinal MS Antibody
- Soft-NMOS
- Transverse Myelitis Ab
- Vision Loss Ab
Feedback
